• Consolidated sales of €20.5 million, up +7.0% at constant exchange rates

• Continued strong growth in France, up +8.2%, representing 76% of Group sales

• Trax CR? knee implant receives FDA approval in the United States

VALENCE, France, November 23, 2023--(BUSINESS WIRE)--Regulatory News:

Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible), French leader on the global surgical technology market for lower-limb orthopedics, announced its consolidated sales for the first quarter of the 2023-24 financial year.

Olivier Jallabert, Chief Executive Officer of Amplitude Surgical, comments: "In the first quarter of the 2023-24 financial year, Amplitude Surgical continued its growth from the previous year, posting an increase of +7.0% at constant exchange rates compared with the first quarter of 2022-23. Sales growth was driven in particular by an 8.2% increase in business in France, which benefited from a favorable sales dynamic".

Q1 sales for fiscal 2023-2024

In the first quarter (July-September 2023) of the 2023-24 financial year, Amplitude Surgical posted sales of €20.5 million, up 5.7% and 7.0% at constant exchange rates.

Sales in France rose by 8.2%, while international distributors were up 13.3%, and the Group's international subsidiaries recorded a 2.9% drop at current exchange rates and a 2.2% rise at constant exchange rates.

Amplitude Surgical's direct sales (French market and international subsidiaries), which account for almost 92% of total Group sales, rose by 6.5% at constant exchange rates.

In France, the Group continues to benefit from a favorable sales dynamic, as in the previous year.
France accounts for some 76% of Group sales.

For international subsidiaries, overall performance was almost stable, but business levels showed variations from one region to another: business was up at constant exchange rates in Belgium, Australia and South Africa, while Germany, Brazil and Switzerland saw a decline in sales.

Trax CR? knee implant receives FDA approval in the United States

Amplitude Surgical has received clearance from the US Food and Drug Administration (FDA) for its Trax CR? implant, which addresses degenerative knee pathologies and enables the preservation of cruciate knee ligaments. This regulatory approval will enable Amplitude to market this product in geographical areas that accept the FDA approval as a reference.